Results 61 to 70 of about 11,522 (197)

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein [PDF]

Immunity, 2018
Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan ...
Gilchuk, Pavlo, Kuzmina, Natalia, Ilinykh, Philipp A, Huang, Kai, Gunn, Bronwyn M, Bryan, Aubrey, Davidson, Edgar, Doranz, Benjamin J, Turner, Hannah L, Fusco, Marnie L, Bramble, Matthew S, Hoff, Nicole A, Binshtein, Elad, Kose, Nurgun, Flyak, Andrew I, Flinko, Robin, Orlandi, Chiara, Carnahan, Robert, Parrish, Erica H, Sevy, Alexander M, Bombardi, Robin G, Singh, Prashant K, Mukadi, Patrick, Muyembe-Tamfum, Jean Jacques, Ohi, Melanie D, Saphire, Erica Ollmann, Lewis, George K, Alter, Galit, Ward, Andrew B, Rimoin, Anne W, Bukreyev, Alexander, Crowe, James E   +31 more
openaire   +4 more sources

Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop

Cell Reports, 2018
Summary: Monoclonal antibodies (mAbs) with pan-ebolavirus cross-reactivity are highly desirable, but development of such mAbs is limited by a lack of a molecular understanding of cross-reactive epitopes.
Charles D. Murin, Jessica F. Bruhn, Zachary A. Bornholdt, Jeffrey Copps, Robyn Stanfield, Andrew B. Ward   +5 more
doaj   +1 more source

Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis

Human Vaccines & Immunotherapeutics, 2021
Clinical development of Ebola virus vaccines (EVV) was accelerated by the West African Ebola virus epidemic which remains the deadliest in history. To compare and rank the EVV according to their immunogenicity and safety.
Alhassane Diallo, Miguel Carlos-Bolumbu, Minerva Cervantes-Gonzalez, Veronika Wozniak, Mamadou Hassimiou Diallo, Boubacar Djelo Diallo, Alexandre Delamou, Florence Galtier   +7 more
doaj   +1 more source

Ebolavirus vaccines for humans and apes [PDF]

Current Opinion in Virology, 2012
Because of high case fatality proportions, person-to-person transmission, and potential use in bioterrorism, the development of a vaccine against ebolavirus remains a top priority. Although no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinical testing of countermeasures has been made.
Hugues, Fausther-Bovendo, Sabue, Mulangu, Nancy J, Sullivan   +2 more
openaire   +2 more sources

Strategic Preparedness of Broad‐Spectrum Antivirals for Rapid Response Towards Next Pandemics

Small Science, Volume 6, Issue 1, January 2026.
Nanoengineered broad‐spectrum antivirals (BSAs) represent a transformative approach to pandemic preparedness. Unlike virus‐specific drugs requiring separate development, BSAs act across multiple viral families through nanoengineering strategies that enhance solubility, bioavailability, and host‐targeted activity.
Sanoj Rejinold N, Geun‐woo Jin, Jin‐Ho Choy   +2 more
wiley   +1 more source

Nicotiana benthamiana as a Source of Cowpea Mosaic Virus‐Derived Particles That Specifically Package Designer RNAs

Plant Biotechnology Journal, Volume 24, Issue 1, Page 159-170, January 2026.
ABSTRACT The coupling of replication and encapsidation in the bipartite plant virus, cowpea mosaic virus (CPMV), has been used to specifically incorporate designer RNA molecules into viral particles via transient expression in Nicotiana benthamiana. This is achieved by placing the desired RNA sequence between the 5′ and 3′ UTRs of CPMV RNA‐2 so that ...
H. Peyret, S. N. Shah, Y. Meshcheriakova, J.‐W. Jung, K. Saunders, G. P. Lomonossoff   +5 more
wiley   +1 more source

Estimating the reproduction number of Ebola virus (EBOV) during the 2014 outbreak in West Africa [PDF]

, 2014
The 2014 Ebola virus (EBOV) outbreak in West Africa is the largest outbreak of the genus Ebolavirus to date. To better understand the spread of infection in the affected countries, it is crucial to know the number of secondary cases generated by an ...
Althaus, Christian L.
core   +2 more sources

Ebola Virus Localization in the Macaque Reproductive Tract during Acute Ebola Virus Disease. [PDF]

, 2018
Sexual transmission of Ebola virus (EBOV) has been demonstrated more than a year after recovery from the acute phase of Ebola virus disease (EVD). The mechanisms underlying EBOV persistence and sexual transmission are not currently understood.
Bernbaum, John G., Hagen, Katie R., Holbrook, Michael R., Huzella, Louis M., Jahrling, Peter B., Johnson, Reed F., Perry, Donna L., Schnell, Matthias J.   +7 more
core   +1 more source

High prevalence of IgG antibodies to Ebola virus in the Efé pygmy population in the Watsa region, Democratic Republic of the Congo [PDF]

, 2016
Background Factors related to the natural transmission of Ebola virus (EBOV) to humans are still not well defined. Results of previous sero-prevalence studies suggest that circulation of EBOV in human population is common in sub- Saharan Africa.
Afounde, Afongenda, Borchert, Matthias, Kulidri, Amayo, Mulangu, Sabue, Muyembe-Tamfum, Jean-Jacques, Paweska, Janusz, Swanepoel, Robert, Tshomba, Antoine, Van der Stuyft, Patrick   +8 more
core   +1 more source

Virological diagnosis of Ebolavirus infection

Pathology, 2015
Ebolaviruses, and the other viral causes of haemorrhagic fevers (VHF) have always posed special problems for diagnostic laboratories. These arise from the rarity of human infections, minimal documented experience with test delivery and interpretation, the paucity of established commercial or in-house assays, the lack of clinical material for test ...
Smith, D.W., Rawlinson, W.D., Kok, J., Dwyer, D.E., Catton, M.   +4 more
openaire   +2 more sources